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Pasteurella multocida is a Gram-negative multispecies pathogen and the causative agent of fowl cholera, a serious disease of
poultry which can present in both acute and chronic forms. The major outer membrane component lipopolysaccharide (LPS) is
both an important virulence factor and a major immunogen. Our previous studies determined the LPS structures expressed by
different P. multocida strains and revealed that a number of strains belonging to different serovars contain the same LPS biosyn-
thesis locus but express different LPS structures due to mutations within glycosyltransferase genes. In this study, we report the
full LPS structure of the serovar 4 type strain, P1662, and reveal that it shares the same LPS outer core biosynthesis locus, L3,
with the serovar 3 strains P1059 and Pm70. Using directed mutagenesis, the role of each glycosyltransferase gene in LPS outer
core assembly was determined. LPS structural analysis of 23 Australian field isolates that contain the L3 locus revealed that at
least six different LPS outer core structures can be produced as a result of mutations within the LPS glycosyltransferase genes.
Moreover, some field isolates produce multiple but related LPS glycoforms simultaneously, and three LPS outer core structures
are remarkably similar to the globo series of vertebrate glycosphingolipids. Our in-depth analysis showing the genetics and full
range of P. multocida lipopolysaccharide structures will facilitate the improvement of typing systems and the prediction of the
protective efficacy of vaccines.
Pasteurella multocida is a Gram-negative pathogen that causes arange of diseases in wild and domestic animals (1). These dis-
eases include fowl cholera in poultry (2), hemorrhagic septicemia
and shipping fever in ruminants (3), and atrophic rhinitis and
respiratory disease in pigs (4), all of which cause significant eco-
nomic losses to primary industries worldwide. P. multocida can
also cause human infections following animal bites or close con-
tact with domestic animals (5). Current classification of P. multo-
cida strains combines Heddleston lipopolysaccharide (LPS) typ-
ing with Carter capsular typing, either by traditional serological
methods or by multiplex PCR (6–8). P. multocida strains are cur-
rently classified into 5 capsular serogroups (A, B, D, E, and F) and
16 Heddleston LPS serovars (6, 8).
Protective immunity against P. multocida is generally consid-
ered to be mediated humorally, with protective antibodies di-
rected primarily, but not exclusively, against the LPS antigen lo-
cated on the surface of the P. multocida cell. Although both live
and killed vaccines are available for protection against P. multo-
cida infection, few afford good levels of protection against strains
expressing different LPS (9, 10). Therefore, elucidating the full
range of LPS structures expressed by P. multocida strains, includ-
ing field isolates, and understanding the role of LPS in protective
immunity are crucial for the formulation of effective, cross-pro-
tective vaccines.
The LPS structures produced by P. multocida type strains rep-
resenting theHeddleston serovars 1, 2, 5, 8, 9, 13, and 14 have been
determined, as well as the structure of the LPS expressed by the
genome-sequenced serovar 3 strain Pm70 (11–17). Some P. mul-
tocida strains can produce two LPS inner core glycoforms simul-
taneously, termed glycoform A and glycoform B. The inner core
glycoform A is produced by all strains examined to date and con-
tains a single phosphorylated 3-deoxy-D-manno-octulosonic acid
(Kdo) residue that is substituted with a phosphoethanolamine
(PEtn) residue (16). This glycoformalso contains a second glucose
residue (Glc II) attached to the 6 position of the first heptose (Hep
I). The inner core glycoformBcontains twoKdo residues anddoes
not have the additional Glc on Hep I. LPS structural analysis of a
range of P. multocida strains representing seven serovars has re-
vealed that the most variable part of the molecule is the outer core
(structure beyond Glc I). Analysis of the corresponding LPS outer
core biosynthesis locus in each strain revealed that although some
shared a nearly identical locus, they expressed different LPS mol-
ecules due to pointmutations or deletionswithin LPSbiosynthesis
genes (11, 13). In this study, we report that the LPS outer core
biosynthesis locus, first identified in Pm70 (17, 18) and named L3
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in this study, is found in the serovar 3 and serovar 4 type strains
(P1059 and P1662) and in 23 Australian field isolates. Each of
these strains express the same conserved inner core structure, but
the strains display significant variability in the length of the LPS
outer core and in the number of LPS glycoforms produced simul-
taneously.We also determined the role of each of the L3 LPS outer
core glycosyltransferase genes in the assembly of the LPS outer
core.
MATERIALS AND METHODS
Bacterial strains, plasmids,media, andgrowth conditions.Thebacterial
strains and plasmids used in this study are listed in Table 1. Escherichia coli
was grown routinely in Luria-Bertani broth. P. multocida was grown in
nutrient broth, brain heart infusion (BHI), or heart infusion (HI) broth.
Solid media were obtained by the addition of 1.5% (wt/vol) agar. When
required, the media were supplemented with kanamycin (50 g/ml),
spectinomycin (50 g/ml), or tetracycline (2.5 g/ml). To isolate LPS
from the P. multocida serovar 4 type strain (P1662), 2 liters of an early-
log-phase culture of P. multocida (grown in BHI at 37°C with shaking at
200 rpm) was used to inoculate 24 liters of BHI in a 28-liter NBS fer-
menter. The culture was grown for 18 h at 37°C with shaking at 200 rpm,
with aeration at 24 liters min1 and 20% O2 saturation. Following treat-
ment with hyaluronidase for 1 h (1 g; Sigma) to remove capsularmaterial,
phenol (2% final concentration) was added and the culture incubated at
room temperature for 4 h to kill bacteria, which were then harvested with
a Sharples continuous-flow centrifuge. For compositional analysis of LPS
produced by the Heddleston serovar 3 type strain (P1059) and the Aus-
tralian field isolates, small quantities of LPS were isolated from plate-
grown cells as described previously (19).
DNA manipulations. Restriction digests and ligations were per-
formed using enzymes and buffers obtained fromNEBor RocheDiagnos-
tics GmbH. Plasmid DNA and genomic DNAwere prepared using a plas-
mid minikit from Qiagen and a genomic DNA extraction kit from RBC,
respectively. PCR amplification of DNA was performed using Taq DNA
polymerase or the ExpandHigh Fidelity PCR system (RocheDiagnostics),
and amplified fragments were purified using a Qiagen PCR purification
kit. The oligonucleotides used in this study were synthesized by Sigma,
Australia, and are listed in Table S1 in the supplemental material. Prepa-
ration of electrocompetent P. multocida and electroporation conditions
were as described previously (20). DNA sequencing reactions and cycle
conditions using either plasmid DNA or PCR products as templates were
performed using BigDye Terminator, version 3.1 (Applied Biosystems),
per themanufacturer’s instructions, with the followingmodifications: 1.5
l of 10 Taq PCR buffer (Roche) and 1 l of BigDye Terminator, ver-
sion 3.1, were used in a 15-l (total volume) reaction mixture. For direct
sequencing of P. multocida genomic DNA, reaction and cycle conditions
were as described previously (21), with the following modifications: reac-
tions were performed in a 40-l volume with 3 l 10 Taq PCR buffer
(Roche), 13 pmol of oligonucleotide, and 4 l of BigDye Terminator,
version 3.1 (Applied Biosystems). All DNA sequenceswere determined on
a capillary-platform genetic analyzer (model 3730; Applied Biosystems)
and analyzed with Vector NTI Advance 11 (Invitrogen). Amino acid se-
quence alignments were conducted using BLAST and Clustal W2.
Construction of P. multocida TargeTron mutants. For inactivation
of genes in P. multocida strain P1059, we used the TargeTron method
(Sigma-Aldrich) ofmutagenesis as described previously (20), but with the
following modifications. To assist in the selection of P. multocida trans-
formants containing an integrated intron, the plasmid pAL692 (20) was
modified to introduce a kanamycin resistance gene, aph3, into the intron.
Briefly, the aph3 gene was amplified from pAL99 (Table 1) by using the
primersBAP6796andBAP6797and thencloned intoMluI-digestedpAL692,
generating the plasmid pAL953 (Table 1). Retargeting of the intron within
pAL953was performedper the instructions of theTargeTronuser’smanual,
using oligonucleotides designed by the TargeTron design site (Sigma-
Aldrich) (see Table S1 in the supplemental material). Each plasmid con-
taining an intron correctly targeted to the target gene (pAL1003,
pAL1004, and pAL1006) (Table 1) was used to transform the P. multocida
serovar 3 type strain (P1059) by electroporation; transformants contain-
ing the plasmid and/or integrated intron were selected on solid agar with
kanamycin. Mutants were then cured of replicating plasmid by overnight
growth in nutrient broth without antibiotic selection, and transformants
containing the intronwere identified by patching ontoHI agar containing
spectinomycin or kanamycin. Kanamycin-resistant, spectinomycin-sen-
sitive transformants were then screened for the correct intron insertion by
colony PCR using one oligonucleotide located within the target gene and
one locatedwithin the intron (EBSuniversal). To confirm integration into
the target gene and to determine if there were any additional intron inser-
tions elsewhere in the genome, direct sequencing from genomic DNAwas
performed using the intron-specific EBS universal primer (Table 1) to-
gether with DNA isolated from each TargeTron mutant. Mutants that
gave unambiguous sequencing data identical to the target gene sequence
were selected for further study.
trans-Complementation of mutants. For complementation of the
kanamycin-resistant TargeTron mutants, the P. multocida expression
plasmid pAL99 was modified to remove the kanamycin resistance
gene, aph3, and replace it with the aadA or tetM gene, conferring
spectinomycin (pAL99S) or tetracycline (pAL99T) resistance, respec-
tively (Table 1). The plasmid pAL99 was amplified using two outward-
firing primers (BAP5358 and BAP5359 [see Table S1 in the supple-
mental material]) flanking aph3, digested with EcoRV, and then
ligated to an EcoRV-digested PCR-amplified fragment containing ei-
ther the aadA gene (amplified from pUA826 by using primers
BAP5360 and BAP5361) or the tetM gene (amplified from Tn916 [in
strain AL523] by using primers BAP7134 and BAP7135), generating
pAL99S or pAL99T, respectively.
For complementation of each of the P. multocida mutants, PCR
amplifications were performed using P1059 genomic DNA and the
appropriate pair of oligonucleotides flanking the target gene (see Table
S1 in the supplemental material). Each product was digested with the
appropriate restriction enzyme and then ligated to appropriately di-
gested pAL99, pAL99S, or pAL99T (Table 1), such that transcription of
each gene would be driven by the constitutive P. multocida tpiA pro-
moter. Each plasmid was then introduced into the corresponding P.
multocidamutant, generating the complemented strain (Table 1). As a
control, the appropriate empty vector was introduced separately into
each mutant (Table 1).
Isolation and purification of lipopolysaccharide. LPS was isolated
and purified as described previously (16). O-deacylated LPS (LPS-OH),
core oligosaccharide (OS), and completely deacylated LPS were all iso-
lated and purified from LPS as described previously (16).
Analytical methods, MS, and NMR spectroscopy. Sugars were
determined as their alditol acetate derivatives, and linkage analysis was
performed following methylation analysis by gas-liquid chromatogra-
phy–mass spectrometry (GLC-MS) and electrospray mass spectrometry
(ES-MS) as described previously. To determine exact locations and link-
age patterns of residues, nuclear magnetic resonance (NMR) techniques
were performed as described previously (16). The assignment of 1H reso-
nances was achieved using correlation spectroscopy (COSY), total corre-
lation spectroscopy (TOCSY), and nuclear Overhauser effect spectros-
copy (NOESY). The assignment of 13C resonances was achieved using
13C-1H heteronuclear single-quantum coherence (HSQC) and 13C-1H
HSQC-TOCSY NMR. To identify the locations of PEtn substitutions,
31P-1H heteronuclear multiple-quantum coherence (HMQC) experi-
ments were performed (16).
Nucleotide sequence accession numbers. Sequence data for the
P1059 and P1662 outer core biosynthesis loci have been deposited in
GenBank under accession numbers KF314825 and KF314826, respec-
tively.
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TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant description Source or referencea
Strains
E. coli DH5 deoR endA1 gyrA96 hsdR17(rK
mK
) recA1 relA1 supE44 thi-1 (lacZYA-argF)U169 80dlacZM15 F Bethesda Research
Laboratories
P. multocida strains
AL523 P. multocida VP161 strain containing Tn916 carrying tetM This study
AL539 VP161 insertional gatAmutant generated using pAL290; no expression of hptE due to polar effects of the
gatA insertion
This study
AL806 VP161 gatAmutant (AL539) containing pAL446
AL2116 P1059 gatF (pm1141) TargeTron mutant of P1059 This study
AL2117 P1059 natB (pm1140) TargeTron mutant of P1059 This study
AL2155 P1059 gatG (pm1139) TargeTron mutant of P1059 This study
AL2192 P1059 gatGmutant containing pAL1022 This study
AL2297 P1059 gatFmutant containing pAL1046 This study
AL2299 P1059 natBmutant containing pAL1045 This study
AL2354 P1059 natBmutant containing vector pAL99T This study
AL2355 P1059 gatFmutant containing vector pAL99T This study
AL2395 P1059 gatGmutant containing vector pAL99S This study
P1059 Heddleston serovar 3 type strain 32
P1662 Heddleston serovar 4 type strain 32
PM1 P. multocida turkey isolate 33
PM3 P. multocida turkey isolate 33
PM8 P. multocida turkey isolate 33
PM18 P. multocida chicken isolate 33
PM48 P. multocida chicken isolate 33
PM72 P. multocida chicken isolate 33
PM146 P. multocida chicken isolate 34
PM1075 P. multocida field isolate MRG culture collection
PM1098 P. multocida field isolate MRG culture collection
PM1099 P. multocida field isolate MRG culture collection
PM1103 P. multocida field isolate MRG culture collection
PM1120 P. multocida chicken isolate MRG culture collection
PM1153 P. multocida chicken isolate MRG culture collection
PM1205 P. multocida emu isolate MRG culture collection
PM1258 P. multocida chicken isolate MRG culture collection
PM1268 P. multocida chicken isolate MRG culture collection
PM1320 P. multocida chicken isolate MRG culture collection
PM1369 P. multocida chicken isolate MRG culture collection
PM1434 P. multocida chicken isolate MRG culture collection
PM1439 P. multocida chicken isolate MRG culture collection
PM1441 P. multocida turkey isolate MRG culture collection
PM1470 P. multocida turkey isolate MRG culture collection
PM1474 P. multocida duck isolate MRG culture collection
Plasmids
pAL99 P. multocida expression plasmid (Kanr) which contains the P. multocida constitutive Ptpi promoter 35
pAL99S P. multocida expression plasmid (Specr); derivative of pAL99 This study
pAL99T P. multocida expression plasmid (Tetr); derivative of pAL99 This study
pAL290 pUA826 derivative containing an internal fragment of gatA This study
pAL446 Complete gctC and hptE genes from Pm70 cloned into pAL99 This study
pAL692 P. multocida plasmid (Specr) containing TargeTron group II intron 20
pAL953 pAL692 with aph3 (Kanr) inserted into TargeTron group II intron This study
pAL1003 pAL953 retargeted to natB by using primers BAP6851/6852/6853 This study
pAL1004 pAL953 retargeted to gatG by using primers BAP6854/6855/6856 This study
pAL1006 pAL953 retargeted to gatF by using primers BAP6864/6865/6866 This study
pAL1022 Complete gatG gene cloned into pAL99S This study
pAL1045 Complete natB gene cloned into pAL99T This study
pAL1046 Complete gatF gene cloned into pAL99T This study
pUA826 Mob R6K replicon; single-crossover mutagenesis vector; Apr Spcr 36
a MRG, Microbiology Research Group, Queensland Alliance for Agriculture and Food Innovation, University of Queensland, Australia.
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RESULTS
Analyses of LPS outer core biosynthesis loci. The region of the
genome containing the LPS outer core biosynthesis locus in the
serovar 3 and 4 type strains (P1059 and P1662, respectively) was
sequenced, and the sequences were found to be 99% identical to
each other and also to the equivalent locus in Pm70 (Fig. 1A) (18).
However, the sequence of the locus in the serovar 4 type strain
(P1662) contained a nonsense mutation within natC due to a
C291A nucleotide substitution. In keeping with our function-
based nomenclature of P. multocida LPS glycosyltransferases (19),
we have named the orthologues of the Pm70 glycosyltransferase
genes in the serovar 3 and 4 type strains natC (pm1138), gatG
(pm1139), natB (pm1140), gatF (pm1141), gctC (losA), and hptE
(pm1144) (Fig. 1A). The LPS outer core biosynthesis locus com-
mon to all three strains (Pm70, P1059, and P1662) was named L3
(Fig. 1A).
Structural analyses of P. multocida LPS derived from the se-
rovar 3 and 4 type strains (P1059 and P1662). Sugar analysis of
the purified LPS isolated from the serovar 4 type strain (P1662)
revealed glucose (Glc), galactose (Gal), and L-glycero-D-manno-
heptose (LD-Hep), in an approximate ratio of 2:1:3. A small
amount of N-acetylglucosamine (GlcNAc) was also identified, as
is often observed for sugar analyses of LPS and presumably derives
from lipid A. In order to separate and detect closely related glyco-
forms, capillary electrophoresis coupled with electrospray ioniza-
tionmass spectrometry (CE-MS) was used to analyze the O-deac-
ylated LPS (LPS-OH) (Table 2). This analysis revealed major
triply charged ions atm/z 1,025.4 and 1,066.2, corresponding to a
composition of 5Hex, 4Hep, Kdo-P, 2PEtn, and O-deacylated
lipid A (lipid A-OH) for the smaller molecule and an additional
PEtn moiety for the larger molecule. Glycoforms with one or no
PEtn residues were also observed. Similarly, MS analysis of the
nonfractionated core OS suggested a composition of 5Hex, 4Hep,
2PEtn, and Kdo as the major glycoform. Interestingly, there was
no evidence of any glycoforms containing twoKdo residues (inner
core glycoform B). Methylation analysis of the fractionated core
OS (fraction 15) allowed determination of the linkage pattern of
the molecule, which revealed the presence of terminal Glc, termi-
nal Gal, 4-substituted Glc, and terminal LD-Hep in approximately
equimolar amounts, with 6-substituted Glc, 2-substituted LD-
Hep, 4,6-disubstituted LD-Hep, and 3,4,6-trisubstituted LD-Hep
identified in smaller amounts.
FIG 1 (A) Schematic representation of the genetic organization of the P. multocida L3 LPS outer core biosynthesis locus, which is common to serovars 3 and 4.
Genes involved in LPS outer core assembly are shown in white. Conserved genes unrelated to LPS biosynthesis are shown in gray. Original gene annotation
numbers for Pm70 are shown below the diagram. (B) Schematic representation of the LPS structure expressed by the P. multocida serovar 3 and 4 type strains
(P1059 and P1662, respectively). Only inner core glycoform A is shown. The P. multocida glycosyltransferase genes predicted to be required for assembly of the
outer core are shown below each linkage on the structure expressed by P1059. The rare addition of GalNAc II onto the P1059 LPS is shownwith a dotted line and
in gray. The specific number and position of phosphoethanolamine (PEtn) residues attached to each LPS structure are strain dependent; nonstoichiometric
additions of PEtn are shown with dotted lines. Regions of the L3 LPS that are identical to the oligosaccharide components of the vertebrate glycosphingolipids,
Forssman, P, and Pk, are shown boxed in the Pm70 structure. GalNAc, N-acetyl-galactosamine; Gal, galactose; Glc, glucose; Hep, heptose; PEtn, phosphoetha-
nolamine; Kdo, 3-deoxy-D-manno-octulosonic acid; P, phosphate.
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In order to elucidate the exact locations and linkage patterns of
the carbohydrate residues, NMR studies were performed on the
core oligosaccharide fraction that gave the most resolved and ho-
mogeneous spectrum (fraction 14). The inner core oligosaccha-
ride 1H and 13C resonances were assigned with reference to the
published data for the structurally related oligosaccharides from
P. multocida strains belonging to serovars 1, 2, 3, and 5 and re-
vealed that the serovar 4 strain elaborated the previously identified
conserved inner core structure (Hep I to IV and Glc I and II)
(Table 3) (12, 15–17).
The outer core residues of the oligosaccharide extension be-
yond Hep IV in strain P1662 were characterized by COSY,
TOCSY, and NOESY experiments (Fig. 2). In addition to the res-
idues of the conserved inner core structure, a glucose residue (Glc
III) was identified, based on a characteristic spin system inTOCSY
experiments. Two spin systems were actually identified for this
residue, with proton resonances at H-1 (4.76 ppm), H-2 (3.53
ppm), H-3 (4.13 ppm), H-4 (3.67 ppm), H-5 (3.73 ppm) and
H-6ab (4.23, 4.10 ppm) in one system and atH-1 (4.75 ppm), H-2
(3.51 ppm), H-3 (4.11 ppm), H-4 (3.60 ppm), H-5 (3.60 ppm),
and H-6ab (3.93, 3.75 ppm) in the other system. Both exhibited
internuclear Overhauser effect (inter-NOE) connectivities from
the anomeric protons to a resonance at 4.17 ppm (Fig. 2). This
resonance was assigned as the proton at the 4-position of the Hep
IV residue by virtue of 13C-1H HSQC and 13C-1H HSQC-TOCSY
experiments (data not shown). The identification of two spin sys-
tems became apparent when 31P-1H HMQC experiments were
performed in conjunction with the homonuclear NMR data,
which revealed the presence of two PEtn residues linked to both
theH-3 (4.13 ppm) andH-6ab (4.23, 4.10 ppm) resonances in one
spin system and to only theH-3 resonance (4.11 ppm) in the other
system (Fig. 2). A further glucose residue (Glc IV) was identified,
based on a characteristic spin system in TOCSY experiments, with
H-1 (4.72 ppm), H-2 (3.44 ppm), H-3 (3.70 ppm), H-4 (3.68
ppm), H-5 (3.66 ppm), and H-6ab (3.98, 3.81 ppm) resonances
being identified. An inter-NOE connectivity from the anomeric
proton ofGlc IV to a resonance at 4.33 ppmwas identified (Fig. 2).
This resonance was assigned as the proton at the 6-position of the
Hep IV residue by virtue of 13C-1H HSQC and 13C-1H HSQC-
TOCSY experiments (data not shown). This assignment, coupled
TABLE 2 Negative-ion CE-ES-MS data and proposed compositions of O-deacylated LPS (LPS-OH) and core OS from the Heddleston serovar 3 and
4 type strains (P1059 and P1662), and proposed compositions of LPS-OH from the P1059 TargeTron mutants
Study and serovar (description)
Observed ions (m/z) Molecular mass (Da)a
Relative
intensity Proposed composition(MH) (M 4H)4 (M 3H)3 (M 2H)2 Observed Calculated
Serovar study
Serovar 3 (P1059) 1,106.5 3,322 3,320.0 0.2 HexNAc, 6Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
LPS-OH 1,147.3 1,721.2 3,444 3,443.0 1.0 HexNAc, 6Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
889.8 1,188.2 3,568 3,566.0 0.8 HexNAc, 6Hex, 4Hep, Kdo-P, 3PEtn, lipid A-OH
Serovar 4 (P1662)
LPS-OH 707.4 943.5 2,833.6 2,831.6 0.2 5Hex, 4Hep, Kdo-P, lipid A-OH
738.0 984.3 1,477.2 2,956.0 2,954.7 0.5 5Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
768.6 1,025.4 1,538.7 3,079.0 3,077.7 1.0 5Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
799.5 1,066.2 3,202.2 3,200.7 0.5 5Hex, 4Hep, Kdo-P, 3PEtn, lipid A-OH
Core OS 899.1 1,800.2 1,799.5 0.2 5Hex, 4Hep, aKdob
960.3 1,922.6 1,922.6 0.8 5Hex, 4Hep, PEtn, aKdob
1,022.1 2,046.2 2,045.7 1.0 5Hex, 4Hep, 2PEtn, aKdob
GctC study
AL539
LPS-OH (gatA polar mutant) 709.7 1,064.9 2,131.9 2,130.9 0.2 Hex, 3Hep, 2Kdo, lipid A-OH
717.0 1,075.9 2,153.9 2,152.9 1.0 2Hex, 3Hep, Kdo-P, lipid A-OH
LPS-OH 758.0 1,137.4 2,276.9 2,276.0 0.6 2Hex, 3Hep, Kdo-P, PEtn, lipid A-OH
773.5 1,160.9 2,323.7 2,323.1 0.1 Hex, 4Hep, 2Kdo, lipid A-OH
780.5 1,171.5 2,344.8 2,345.1 0.2 2Hex, 4Hep, Kdo-P, lipid A-OH
822.1 1,233.2 2,469.2 2,468.2 0.1 2Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
AL806 LPS-OH (AL539 gctC,
hptE)
691.8 923.2 2,772.1 2,770.5 0.5 3Hex, 4Hep, 2Kdo, PEtn, lipid A-OH
930.4 2,794.2 2,792.4 0.3 4Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
728.5 971.4 2,917.6 2,915.5 1.0 4Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
GatF study
AL2116 LPS-OH (gatFmutant) 697.7 930.7 1,395.5 2,794.0 2,792.4 0.3 4Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
728.3 971.2 1,457.2 2,916.6 2,915.5 1.0 4Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
AL2297 LPS-OH (gatF
mutant gatF)
1,174.0 3,525.0 3,523.2 0.4 2HexNAc, 6Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
1,215.0 3,648.0 3,646.3 1.0 2HexNAc, 6Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
GatG study
AL2155 LPS-OH (gatGmutant) 768.9 1,025.3 3,079.2 3,077.7 1.0 5Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
799.6 1,066.2 3,202.0 3,200.8 1.0 5Hex, 4Hep, Kdo-P, 3PEtn, lipid A-OH
AL2192 LPS-OH (gatG
mutant gatG)
1,106.5 3,322.5 3,320.0 1.0 HexNAc, 6Hex, 4Hep, Kdo-P, lipid A-OH
1,147.5 3,445.5 3,443.1 0.9 HexNAc, 6Hex, 4Hep, Kdo-P, lipid A-OH
1,174.0 3,525.0 3,523.2 0.3 2HexNAc, 6Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
1,215.0 3,648.0 3,646.3 0.4 2HexNAc, 6Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
NatB study
AL2117 LPS-OH (natBmutant) 768.7 1,025.4 3,079.0 3,077.7 0.8 5Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
809.4 1,079.5 3,241.5 3,239.9 1.0 6Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
AL2299 LPS-OH (natB
mutant natB)
1,174.0 3,525.0 3,523.2 0.4 2HexNAc, 6Hex, 4Hep, Kdo-P, PEtn, lipid A-OH
1,215.0 3,648.0 3,646.3 1.0 2HexNAc, 6Hex, 4Hep, Kdo-P, 2PEtn, lipid A-OH
a Average mass units were used for calculation of molecular mass based on the proposed composition, as follows: lipid A-OH, 952.00; Hex, 162.15; Hep, 192.17; Kdo, 220.18;
anhydro Kdo (aKdo), 202.18; PEtn, 123.05; P, 79.95.
b aKdo, hydrolysis products of Kdo formed during core hydrolysis.
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with the data for the Glc III residue, is consistent with the meth-
ylation analysis data which identified a 4,6-substituted LD-Hep
residue. A terminal galactose residue (Gal I) was identified based
on a characteristic spin system in TOCSY experiments, with H-1
(4.46 ppm), H-2 (3.56 ppm), H-3 (3.67 ppm), and H-4 (3.94
ppm) resonances being identified. An inter-NOE connectivity
from the anomeric proton of Gal I to a resonance at 3.68 ppmwas
identified (Fig. 2). This resonancewas assigned as the proton at the
4-position of the Glc IV residue by virtue of 13C-1H HSQC and
13C-1H HSQC-TOCSY experiments (data not shown). This as-
signment is also consistent with the methylation analysis data,
which identified a 4-linkedGlc residue and a terminal Gal residue.
The identification of two PEtn residues substituting the 3- and
6-positions of Glc III, alongwith evidence for a PEtn residue at the
3-position ofHep II in some glycoforms, combinedwith the iden-
tification of only 2 PEtn residues in total in the core OS, led us to
examine closely the 31P-1H heteronuclear and homonuclearNMR
data (Fig. 2). It became clear that the PEtn at the 6-position of the
Glc III residue was present nonstoichiometrically; however, the
PEtn residue at the 3-position was found to always be present.
Furthermore, the PEtn residue was identified at the 3-position of
the Hep II residue (in the inner core) approximately 20% of the
time. However, the simultaneous expression of all three PEtn res-
idues in the core OS was not identified, perhaps suggesting a mu-
tual exclusivity. Taken together, these data show that the serovar 4
type strain (P1662) produces LPS that is a truncated derivative of
the Pm70 LPS (17), with the exception of one or two additional
PEtn residues on Glc III of the P1662 outer core (Fig. 1B).
As the full structure of the LPS core oligosaccharide from the
serovar 3 strain Pm70 has been determined previously (17), only
CE-MS analysis of LPS-OH was conducted on the serovar 3 type
strain (P1059). Analysis of the P1059 LPS revealed that all LPS
glycoforms lacked the terminal HexNAc; CE-MS analysis of
LPS-OH revealed a major triply charged ion at m/z 1,147.3, cor-
responding to a composition of HexNAc, 6Hex, 4Hep, 2PEtn,
Kdo, and lipid A-OH (Table 2). To confirm this finding, we un-
dertook CE-MS analysis of LPS-OH isolated from two indepen-
dent freeze-dried cultures of strain P1059 that had been sourced
from different collections and found that the LPS composition
consisted mainly of HexNAc, 6Hex, 4Hep, 2PEtn, Kdo, and lipid
A-OH, but trace amounts of the 2HexNAc, 6Hex, 4Hep, 2PEtn,
TABLE 3 1H- and 13C-NMR chemical shifts for the core OS from the Pasteurella multocida serovar 4 type strain, P1662a
M H
K J E CN           L
G F
α-Hep-2-α-Hep3PEtN-3
β-Gal-4-β-Glc-6-α-Hep-6-β-Glc-4-α-Hep-5-Kdo
β-Glc3,6PEtN  -4 α-Glc-6 2
Residue
Chemical shift
Inter-NOEH-1 (C-1) H-2 (C-2) H-3 (C-3) H-4 (C-4) H-5 (C-5) H-6 (C-6) H-7 (C-7)
Hep I (E) 5.03 (97.7) 3.97 (71.4) 3.89 (75.1) 4.22 (75.0) 3.65 (72.7) 4.16 (80.1) 3.88, 3.75 (63.3)
Hep IIb 3-P (F) 5.82 (99.7) 4.28 (80.1) 4.42 (76.4) 4.08 (ND) 3.57 (ND) ND ND 3.89 Hep I H-3
Hep II, no 3-P (F=) 5.65 (100.6) 4.18 (80.8) 3.89 (71.0) 3.89 (67.9) 3.57 (73.1) 4.04 (70.6) 3.75, 3.75 (64.6) 3.89 Hep I H-3
Hep III (G) 5.11 (102.8) 4.02 (71.7) 3.88 (71.8) 3.84 (67.3) 3.81 (72.8) 4.04 (70.6) 3.75, 3.75 (64.6) 4.18 Hep II H-2
Hep IV (K) 4.95 (100.3) 4.15 (70.6) 3.91 (70.7) 4.17 (78.1) 3.94 (71.3) 4.33 (80.2) 3.96, 3.78 (ND) 4.08 Glc I H-6a, 3.76 Glc I H-6b
-Glc (Glc I) (J) 4.63 (104.4) 3.51 (74.4) 3.42 (78.0) 3.58 (70.8) 3.52 (74.9) 4.08, 3.76 (66.3) 4.22 Hep I H-4
-Glc (Glc II) (H) 5.21 (102.5) 3.59 (73.1) 3.81 (74.2) 3.56 (69.8) 3.92 (72.8) 3.93, 3.76 (60.9) 4.16 Hep I H-6
-Glc (Glc III)b 3,6-P (M) 4.76 (103.4) 3.53 (74.0) 4.13 (82.0) 3.67 (69.7) 3.73 (75.4) 4.23, 4.1 (65.7) 4.17 Hep IV H-4
-Glc (Glc III)b 3-P (M=) 4.75 (103.4) 3.51 (74.0) 4.11 (82.0) 3.60 (69.9) 3.60 (76.6) 3.93, 3.75 (61.9) 4.17 Hep I H-4
-Glc (Glc IV) (L) 4.72 (104.5) 3.44 (74.2) 3.70 (75.4) 3.68 (79.7) 3.66 (75.8) 3.98, 3.81 (61.4) 4.33 Hep IV H-6
-Gal (Gal I) (N) 4.76 (103.2) 3.56 (71.3) 3.67 (72.7) 3.94 (68.6) 3.73 (75.5) 3.80, 3.75 (62.0) 3.68 GlcIV H-4
a Chemical shifts were recorded at 25°C and referenced to internal acetone at 2.225 ppm (1H)/31.07 ppm (13C).
b Signals for ethanolamine of phosphoethanolamine at F-3, M-3, and M-6 were observed at 4.19/63.1 and 3.31/41.3.
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FIG 2 NMR analyses of core OS fraction 14 from P. multocida Heddleston
serovar 4 strain P1662. Regions of overlapped COSY (green), TOCSY (red),
and NOESY (purple) spectra (bottom two panels) and the 1H-31P HMQC
(green and purple) spectrum (top panel) of the core OS are shown. Residues
are labeled as indicated in Table 3.
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Kdo, and lipid A-OH glycoform were detected in both samples
(data not shown). A trace amount of the inner core glycoform B
(HexNAc, 5Hex, 4Hep, 2Kdo, PEtn, and lipid A-OH) was also
detected in one of the samples (data not shown).
Characterization of the glycosyltransferases involved in bio-
synthesis of the L3 LPS outer core. The functions of two glyco-
syltransferases (HptE andNatC) encoded within the L3 LPS outer
core biosynthesis locus were determined previously: HptE is re-
quired for the addition of the first outer core sugar, Hep IV (19),
and NatC (annotated as PM1138 in strain Pm70) is an N-acetyl-
galactosyltransferase required for the addition of the last outer
core sugar, GalNAc II (22) (Fig. 1). Previous bioinformatic anal-
ysis of the equivalent region in strain Pm70 indicated that pm1141
(glycosyltransferase family 25) and pm1139 (glycosyltransferase fam-
ily8) likely encode1,4-galactosyltransferases that addGal I andGal II,
respectively, and pm1140 (glycosyltransferase family A) encodes an
N-acetyl-galactosyltransferase that adds GalNAc I (17).
To confirm the predicted functions of these enzymes, the
pm1141, pm1139, and pm1140 orthologues (gatF, gatG, and natB,
respectively) were separately inactivated in the serovar 3 type
strain (P1059), and the effect of each mutation on LPS structure
was determined (Table 2). To confirm that any LPS structural
changes were due specifically to inactivation of the mutated gly-
cosyltransferase, each mutant was complemented with a func-
tional copy of the appropriate transferase provided in trans. Struc-
tural analysis of the mutants revealed that the gatF mutant
(AL2116) was unable to assemble LPS beyond Glc IV and that the
gatG mutant (AL2155) was unable to assemble LPS beyond Gal I
(Fig. 1; Table 2), confirming bioinformatic predictions that GatF
is the galactosyltransferase which adds Gal I to the 4th position of
the Glc IV andGatG is a galactosyltransferase which adds Gal II to
the 4th position of Gal I (Fig. 1). Similarly, analysis of the LPS
produced by the P1059 natB mutant (AL2117) confirmed that
NatB is the 1,3-N-acetyl-galactosyltransferase responsible for the
addition of GalNAc I to Gal II (Fig. 1; Table 2). Importantly, in
each case, complementation experiments showed that mutants
provided with a functional copy of the appropriate transferase in
trans produced full-length LPS (Table 2), while mutants trans-
formed with vector only did not (data not shown).
To determine the role of gctC in LPS outer core assembly, we
used an LPS mutant, AL539, constructed in the serovar 1 strain
VP161, which expresses only the highly conserved inner core LPS,
including Glc I, which is the acceptor molecule for the HptE hep-
tosyltransferase (19). This strainwas transformedwith the expres-
sion plasmid pAL446 containing a functional copy of the L3 gly-
cosyltransferase genes hptE and gctC (PCR amplified from Pm70)
(Table 1). MS (Table 2) and NMR structural analyses (data not
shown) of the LPS produced by the complemented strain (AL806)
revealed that it elaborated an LPS outer core of two terminal Glc
residues linked to the 4- and 6-positions ofHep IV, confirming the
role of the L3 HptE as the 1,6-heptosyltransferase and identifying
that GtcC is a bifunctional glucosyltransferase that adds glucose to
both the 4- and 6-positions of D-Hep IV.
Analysis of genetics underlying P1662 LPS truncation. The
serovar 4 type strain, P1662, produced a truncated LPS structure
terminating at Gal I, suggesting that the 1,4-galactosyltransferase,
GatG, was nonfunctional in this strain. Analysis of the P1662 gatG
sequence indicated that the translated product contained eight
amino acid changes (R85K, V240A, A253D, N259K, R272K,
E277K, V279M, and T284N) compared to the functional GatG
glycosyltransferases expressed by Pm70 and P1059. The Neisseria
meningitidis galactosyltransferase LgtC is 39% identical (57%con-
served) to GatG, and the crystal structure of LgtC has been deter-
mined in complex with both its donor and acceptor molecules
(23). Alignment of LgtC with other family 8 glycosyltransferases,
including GatG (PM1139), identified a number of highly con-
served amino acids critical for interaction with the donor mole-
cule, the acceptor molecule, or the divalent cation Mn2 (23)
FIG 3 Amino acid sequence alignment of GatG (PM1139) from Pasteurella multocida strain Pm70 (Swiss-Prot accession no. Q9CLS0) aligned with the
galactosyltransferase LgtC from Neisseria meningitidis (Swiss-Prot accession no. P96945). Amino acids that are highly conserved within LgtC-related glycosyl-
transferases are highlighted in gray (23). LgtC amino acids involved in binding to Mn2 are marked with squares. Amino acids in LgtC known to interact with
the UDP or galactose region of the nucleotide sugar UDP-galactose are marked with open or filled circles, respectively, while those involved in binding to the
acceptor molecule are marked with triangles (23).
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(Fig. 3). Only one of the eight GatG substitutions identified in
strain P1662 (R85K) was in a highly conserved position (R86 in
LgtC), and this residue is critical for the interaction of LgtC with
the galactose portion of the donor. Therefore, we suggest that the
R85K mutation is responsible for the loss of GatG function in
P1662.
Structural and genetic analyses of LPS biosynthesis in P.
multocida field isolates belonging to genotype L3. To determine
the diversity of LPS structures produced by P. multocida field iso-
lates belonging to LPS genotype L3, we identified 23 P. multocida
isolates from Australian poultry farms that contained L3 LPS
outer core biosynthesis loci. Proposed compositions determined
fromCE-MS analysis of LPS-OHpurified from each of the isolates
(see Table S2 in the supplemental material) indicated that a num-
ber of different LPS structures were produced, ranging from
inner core-only structures (terminating at Glc I) to full-length
structures terminating at GalNAc II (Fig. 4; Table 4). Interest-
ingly, 14 of the isolates simultaneously expressed multiple LPS
glycoforms containing outer core sugar extensions ranging
from 3 to 7 residues (see Table S2), and none of the field isolates
analyzed elaborated an LPS structure terminating with Hep IV
(Fig. 4; see Table S2).
To determine if the truncated LPS structures observed in the
field isolates were the result of mutations within one of the glyco-
syltransferase genes in the L3 LPS outer core biosynthesis locus,
the glycosyltransferase gene predicted to be responsible for the
arrested assembly in each case was amplified by PCR, and the
nucleotide sequence was determined using the same oligonucleo-
tides used for complementation experiments (Table 1). The trans-
lated amino acid sequences were then compared with those of the
functional orthologs in P1059 and Pm70. In eight of the field
isolates, there were clearmutations resulting in an immediate stop
codon or a reading frameshift leading to a stop codon (PM48,
PM1075, PM1120, PM1103, PM1205, PM1258, PM1434, and
PM1439) (Table 4). In five field isolates (PM1, PM3, PM8,
PM1369, and PM1474), there were no changes detected in the
gene examined, although one isolate (PM1) had nucleotide
changes anddeletions in the predicted promoter region.However,
seven of the field isolates contained one or more missense muta-
tions in the genes encoding the predicted inactivated transferase;
two strains (PM18 and PM146) contained mutations within gatF,
two had changes in natC (PM1099 and PM1441), and three
(PM1268, PM1320, and PM1098) contained mutations in gatG
(Table 4).
As noted previously, the structure of N. meningitidis LgtC (a
GatG ortholog) is known, and alignments of GatG from PM1098,
PM1268, and PM1320 (each containing missense mutations)
with LgtC revealed that there were amino acid changes located in
close proximity to residues that are known to be critical in LgtC.
These residues included those required for LgtC to interact with
the UDP portion of the sugar donor (I104, G247, and K250), the
divalent cation Mn2 (D103, D105, and H244), or the acceptor
FIG 4 Schematic representation showing the range of LPS outer core structures expressed by the 23 Australian field isolates containing the L3 outer core
biosynthesis locus. Only the longest LPS outer core structure is shown for strains expressing multiple LPS glycoforms. The specific number and position of
phosphoethanolamine (PEtn) residues attached to each LPS structure are strain dependent and are not shown. GalNAc,N-acetyl-galactosamine; Gal, galactose;
Glc, glucose; Hep, heptose.
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molecule (D130 and F132) (23) (Fig. 3). Therefore, it is highly
likely that the missense mutations in GatG abrogate transferase
function in these field isolates. There are no data available on the
structure of GatF andNatC homologs in other bacteria, so it is not
possible to predict if themissensemutations identified in gatF and
natC were responsible for the altered LPS production observed in
those strains.
DISCUSSION
The strains belonging to the L3 LPS genotype include the first
genome-sequenced P. multocida strain, Pm70, and the Hed-
dleston serovar 3 and 4 type strains (P1059 and P1662, respec-
tively). Using LPS structural analysis of directedmutants followed
by trans-complementation, the role of each of the uncharacterized
transferases in the L3 locus (NatB, GatG, GatF, and GctC) was
defined, andprevious functional predictionswere confirmed (17).
Interestingly, P1059 elaborates only trace quantities of LPS glyco-
forms containing GalNAc II. However, when the P1059 gatF,
gatG, and natBmutants were complemented with the appropriate
wild-type genes, all produced significant levels of the full-length
glycoform containing the terminal GalNAc II (Table 2). This find-
ing strongly suggests that the efficiency of addition of GalNAc II
byNatC is dependent on the rate of production of the appropriate
LPS acceptor molecule (extended to GalNAc I), which in turn is
dependent on the efficiency of the transferases involved in the
earlier steps of LPS assembly.
LPS structural analysis of the strains belonging to LPS genotype
L3, which includes the serovar 3 and 4 type strains, Pm70, and the
23 field isolates analyzed here, revealed that all produced LPS con-
taining the inner core glycoform A (containing Kdo-P), which is
the most common LPS inner core structure produced by P. mul-
tocida. However, the inner core glycoform B (containing Kdo-
Kdo), previously reported by us to be expressed in significant
quantities in the serovar 1 strains VP161 andX73 (15, 16), was not
detected in strain P1662 or in any of the L3 Australian field iso-
lates, although glycoform B was detected in trace amounts in
strain P1059 andwas previously found in LPS isolated fromPm70
(17). Although all strains share the same LPS outer core biosyn-
thesis locus, L3, the length of the LPS outer core structure varied
considerably; Pm70 produced significant quantities of the fully
extended LPS structure, whereas nearly all LPS glycoforms in
strain P1059 lacked the terminal GalNAc II, while the longest of
the LPS glycoforms produced by P1662 terminated at Gal I.While
some of this variation is due to clear mutations inactivating genes
within the L3 locus, some field isolates produced a fully extended
LPS glycoform as well as up to four shorter, but related, outer core
TABLE 4 Detected mutations in LPS outer core biosynthesis loci of P. multocida field isolates
Longest LPS outer core structure detecteda
Predicted gene
disrupted Field isolate Detected mutation(s)b
No detectable outer core hptE PM1075 Q229*
PM1120 Q194*
PM1258 Single nucleotide deletion at position 61
Hep·[Glc]·Glc gatF PM3 None detected
PM8 None detected
PM18 A205T
PM146 S41P, V138M
Hep·[Glc]·Glc·Gal gatG PM1098 C128Y
PM1205 Insertion of 42 nucleotides at position 353
PM1268 I50V, K98R, A253D, D254N, N259K, R272K, E277K, V279M, T284N,
A288D, F297L
PM1320 I50V, K98R, A253D, D254N, N259K, R272K, E277K, V279M, T284N,
A288D, F297L
PM1439 14 nucleotides deleted, positions 496–509
Hep·[Glc]·Glc·Gal·Gal natB PM1369 None detected
PM1474 None detected
Hep·[Glc]·Glc·Gal·Gal·GalNAc natC PM1 Nucleotide changes/deletions in promoter region
PM48 S97*
PM1099 I132N, I206V
PM1103 Deletion/rearrangement between nucleotides 186 and 276
PM1441 K3R, F4L, N7H, G33K, E49K, N62D, F78L, N80S, N105D, E115G, V120I,
Y168D, K173N, Q176R, R193Q, I194V, Q207K, Q281K, I231V, E236K,
E284D, K285Q, E271A, I292M, K296T, L312I, N396K, S397R
PM1434 S97*
Hep·[Glc]·Glc·Gal·Gal·GalNAc·GalNAc None PM72 All genes functional
PM1153 All genes functional
PM1470 All genes functional
a [Glc], residue is attached to the main chain residues via a 1,4 linkage to Hep.
b Compared to nucleotide and amino acid sequences of the equivalent functional orthologues in Pm70 and/or P1059. *, stop codon. GatG residue changes shown in bold are in
close proximity to amino acids predicted to interact with the donor or acceptor molecule or the divalent cation Mn2.
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structures. This intrastrain variation in LPS structure as the result
of truncations in the outer core region has previously been re-
ported forHaemophilus influenzae (24) but has not been observed
in strains belonging to any of the other P. multocida serovars ex-
amined to date. There is no genetic evidence of any phase variation
in P. multocida, but it is possible that the expression of multiple
glycoforms from the same locus could be controlled posttran-
scriptionally via an unknown mechanism. Alternatively, MsbA,
the ABC transporter responsible for “flipping” LPS across the in-
ner membrane (25), may transport an unusually large number of
LPS glycoforms before the outer core region of the LPS has fully
extended.
The LPS produced by strains belonging to the L3 LPS genotype
contains outer core structures remarkably similar to the oligosac-
charide component of P, Pk, and Forssman antigen, found on the
surfaces of many cell types in vertebrates (26). In birds, Forssman
antigen has been identified in the vascular endothelial tissue,
perivascular connective tissue, and hematopoietic organs, includ-
ing the spleen (27). Forssman antigen is also present on the sur-
faces of chicken erythrocytes (28).Notably, P andPk antigenmim-
icry has been reported for other pathogens that express
O-antigen-deficient LPS, including Campylobacter jejuni (29),
Haemophilus influenzae (30), and Neisseria spp. (31).
In summary, we have shown that fowl cholera strains contain-
ing the LPS outer core biosynthesis locus L3 display a remarkable
level of inter- and intrastrain LPS structural heterogeneity. This
group includes the serovar 3 and 4 type strains (P1059 and P1662)
as well as the first genome-sequenced strain, Pm70. This level of
LPS diversity, particularly within a single strain and derived from
a single LPS outer core biosynthesis locus, has not been observed
in any other P. multocida strains examined to date (37). The role
that thesemultiple LPS glycoforms play in disease progression and
immunity is not known, but three of the outer core structures
expressed are identical to the carbohydrate structure in the globo
series of vertebrate glycosphingolipids, i.e., P, Pk, and Forssman
antigen. LPS is considered a major immunogen of Gram-negative
bacteria, but as the vertebrate immune system is tolerant of self-
antigens, theremay be a failure to respond appropriately to strains
expressing these antigens. Thus, it is likely that the expression of
L3 LPS molecules may aid the in vivo survival/persistence of bac-
teria through avoidance of the host immune system.
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